The international journal of biochemistry & cell biology · 2026
Targeting PI3Kγ/AKT1-OCT4/SOX2 axis with eganelisib suppresses tumor growth and prevents ovarian failure in malignant ovarian germ cell tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Yanning, Yi Li, Liu Jinzhu, Chen Quanyu, Ji Yijie, Liu Bingbing, Li Hanbo, Gong Xue, Liu Wenbiao, Li Shuangshuang, Shen Xinghui, Chen Ling
Аннотация
OBJECTIVE: Malignant ovarian germ cell tumors (MOGCTs) predominantly affect children and young women. Cisplatin-based chemotherapy is effective but frequently causes premature ovarian failure (POF). The PI3K/AKT pathway drives both MOGCT pathogenesis and chemotherapy-induced ovarian damage, yet no strategy simultaneously targets both. This study investigates whether the selective PI3Kγ inhibitor eganelisib can exert dual antitumor and ovarian-protective effects by modulating the AKT1-OCT4/SOX2 axis.
METHODS: In this study, we tried to observe eganelisib antitumor effects on the human embryonal carcinoma cell line NCCIT in vitro and in vivo. Ovarian fertility was assessed by estrous cycle, hormone levels, follicular development, embryonic development, and fertility outcomes in mice treated with eganelisib compared with cisplatin. AKT1 overexpression and knockdown were performed to validate functional dependency. Protein interactions between AKT1 and OCT4/SOX2 were evaluated by co-immunoprecipitation.
RESULTS: In vitro, eganelisib suppressed NCCIT cell proliferation, migration, invasion, and stemness via AKT1-dependent disruption of the AKT1-OCT4/SOX2 axis. In vivo, eganelisib achieved antitumor efficacy comparable to cisplatin while preserving ovarian reserve, maintaining hormone balance, and protecting fertility. Mechanistically, eganelisib upregulated PTEN and enhanced GSK3β activity in the ovary without activating stress-related FOXO3/mTOR pathways.
CONCLUSION: Our findings suggest that selective PI3Kγ inhibition with eganelisib may partially dissociate antitumor activity from gonadotoxicity by targeting the shared AKT1-OCT4/SOX2 signaling axis. This dual-purpose strategy offers a promising mechanism-based approach for fertility-concurrent cancer therapy in young patients with MOGCTs.
METHODS: In this study, we tried to observe eganelisib antitumor effects on the human embryonal carcinoma cell line NCCIT in vitro and in vivo. Ovarian fertility was assessed by estrous cycle, hormone levels, follicular development, embryonic development, and fertility outcomes in mice treated with eganelisib compared with cisplatin. AKT1 overexpression and knockdown were performed to validate functional dependency. Protein interactions between AKT1 and OCT4/SOX2 were evaluated by co-immunoprecipitation.
RESULTS: In vitro, eganelisib suppressed NCCIT cell proliferation, migration, invasion, and stemness via AKT1-dependent disruption of the AKT1-OCT4/SOX2 axis. In vivo, eganelisib achieved antitumor efficacy comparable to cisplatin while preserving ovarian reserve, maintaining hormone balance, and protecting fertility. Mechanistically, eganelisib upregulated PTEN and enhanced GSK3β activity in the ovary without activating stress-related FOXO3/mTOR pathways.
CONCLUSION: Our findings suggest that selective PI3Kγ inhibition with eganelisib may partially dissociate antitumor activity from gonadotoxicity by targeting the shared AKT1-OCT4/SOX2 signaling axis. This dual-purpose strategy offers a promising mechanism-based approach for fertility-concurrent cancer therapy in young patients with MOGCTs.